This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Tap the Weight-Loss Drug Market With These ETFs
by Sweta Killa
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
by Zacks Equity Research
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Top Stock Picks for Week of September 16, 2024
by Panel Of Zacks Experts
One of the Largest Pharmaceutical Companies and an Emerging Growth Company are Profiled.
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
by Kinjel Shah
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
by Zacks Equity Research
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Eli Lilly (LLY)
by Ethan Feller
Eli Lilly stock boasts both defensive and growth characteristics
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Stock Reports for Visa, AbbVie & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Best Momentum Stocks to Buy for September 10th
by Zacks Equity Research
LLY, MCO, and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 10, 2024.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
by Zacks Equity Research
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
New Strong Buy Stocks for September 10th
by Zacks Equity Research
CLCO, BCH, ZUO, LLY and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 10, 2024.
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
by Andrew Rocco
The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
by Zacks Equity Research
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.